Disclosures: David Marti-Aguado: Nothing to Disclose, Jose Miguel Carot Sierra: Nothing to Disclose, Aida Villalba Ortiz: Nothing to Disclose, Rose Marie Vallejo Vigo: Nothing to Disclose, Carmen Lara Romero: Nothing to Disclose, Marta Martn-Fernndez: Nothing to Disclose, Matias Fernandez Paton: Nothing to Disclose, Clara Alfaro-Cervello: Nothing to Disclose, Ana Crespo: Nothing to Disclose, Elena Coello-Cordoba: Nothing to Disclose, Victor Merino Murgui: Nothing to Disclose, Salvador Benlloch: Nothing to Disclose, Judith Perez-Rojas: Nothing to Disclose, Victor Carlos Puglia Puglia: Nothing to Disclose, Antonio Ferrandez: Nothing to Disclose, Victoria Aguilera: Nothing to Disclose, Cristina Montn: Nothing to Disclose, M Desamparados Escudero: Nothing to Disclose, PALOMA LLUCH GARCIA: Nothing to Disclose, rocio aller: Nothing to Disclose, Manuel Romero-Gmez: Nothing to Disclose, Luis Marti-Bonmati: Nothing to Disclose 1601 EFFECTS OF LUSEOGLIFLOZIN ON MASLD IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A POOLED META-ANALYSIS OF PHASE III CLINICAL TRIALS Takumi Kawaguchi 1 Kenta Murotani 2 Hiromitsu Kajiyama 3 Hitoshi Obara 2 Hironori Yamaguchi 3 Yuko Toyofuku 4 Fumi Kaneko 4 Yutaka Seino 5 Saeko Uchida 3 , 1 Kurume University School of Medicine, 2 Kurume University, 3 Taisho Pharmaceutical Co., Ltd., 4 Kurume University Hospital, 5 Kansai Electric Power Hospital Background: Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, potentially exerts pleiotropic effects on the liver
The accumulated evidence over recent decades regarding the efficacy of new pharmacological treatments for obesity has positioned the glucagon-like peptide-1 (GLP-1) analogue as a key componentwhether as monoagonists, unimolecular multiagonists, or in combination therapies targeting multiple receptors.1 These drugs have made it possible to achieve previously unthinkable goals in terms of weight reduction and control of various obesity-related comorbidities (Fig
J Neurochem 117:3847
TLR2 regulates allergic airway inflammation and autophagy through PI3K/Akt signaling pathway
